Notification of Preliminary Results

RNS Number : 2761Y
Alliance Pharma PLC
02 March 2017
 

For immediate release

2 March 2017

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

 

Notification of Preliminary Results

 

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, will announce its preliminary results for the year ended 31 December 2016 on Wednesday 29 March 2017.

 

A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

 

For more information please contact Buchanan on 020 7466 5000.

 

For further information:

 

Alliance Pharma plc

+ 44 (0) 1249 466966

John Dawson, Chief Executive

Andrew Franklin, Chief Financial Officer


www.alliancepharma.co.uk


Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Sophie Cowles / Jane Glover




Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield


Corporate Broking: James Black / Toby Adcock


 

Notes to editors:

 

About Alliance Pharma

 

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

 

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORLLFVRVDILIID
UK 100